NDAORALTABLETPriority Review
Approved
Mar 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI (efavirenz, lamivudine and tenofovir disoproxil fumarate) by Viatris (2) is non-nucleoside reverse transcriptase inhibitors [moa]. First approved in 2018.
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate used to treat HIV-1 infection. It works by inhibiting reverse transcriptase, a key enzyme that HIV uses to replicate. This oral, single-tablet regimen simplifies treatment adherence for HIV-positive patients.
$0.001BPart D
PeakProduct is at peak lifecycle with modest Part D penetration (377 claims in 2023), suggesting a stable but potentially commoditized position requiring strong medical and market access support.
Mechanism of Action
Non-Nucleoside Reverse Transcriptase Inhibitors
Pharmacologic Class:
Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYMFI offers exposure to a mature HIV franchise with entrenched competition and commodity pricing dynamics. Roles will emphasize market access, payer strategy, and geographic expansion in emerging markets rather than innovation or clinical development.
Brand Manager
Worked on SYMFI at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.